Patients suffering from severe allergic reactions now have access to a new, needle-free treatment option, as the US Food and Drug Administration (FDA) has approved neffy, a 2 mg epinephrine nasal spray developed by ARS Pharmaceuticals, Inc. How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies Driven by personal loss and inspired by the progress